Cytochrome P450 (CYP) superfamily (CYP)

The Cytochrome P450 (CYP) superfamily is a large and diverse group of heme-containing enzymes that catalyze the oxidation of organic substances, playing a central role in both endogenous metabolism and the detoxification of xenobiotics. Human CYP51A1, or lanosterol 14-alpha demethylase, is a key enzyme in the cholesterol biosynthetic pathway, serving as the human ortholog to the primary target of azole antifungal medications [UniProt: P10613]. Other members of the superfamily, such as CYP3A4, CYP2D6, and CYP2C9, are responsible for the phase I metabolism of the majority of clinical drugs, making them critical determinants of drug efficacy and safety [PubMed: 23588304]. While these enzymes are often viewed as anti-targets due to their involvement in complex drug-drug interactions, specific isoforms like CYP19A1 (aromatase) are primary therapeutic targets in diseases such as breast cancer [NCBI: NBK1984]. Genetic variations across the CYP genes lead to significant differences in metabolic rates among individuals, necessitating pharmacogenetic testing for optimized dosing [PharmGKB]. Consequently, understanding the structural and functional nuances of the CYP superfamily is essential for drug development, toxicology, and personalized medicine [StatPearls: NBK557669].

Other names

CYP450Heme-thiolate monooxygenasesMicrosomal monooxygenaseLanosterol 14-alpha demethylaseCYP51A1

Inhibition of the heme-iron catalytic center or modulation of enzyme expression levels to alter the metabolic clearance of endogenous and exogenous substrates.